Open access
Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI‐Related Adverse Events During IO–TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study
Misato Tomita
Y. Tasaki
S. Hamamoto
T. Osawa
S. Yamashita
Ryuji Matsumoto
Hiroaki Ikoma
K. Kawase
Yoshihisa Mimura
Y. Sugiyama
T. Yasui
Yoko Furukawa-Hibi
Medicine
Abstract
Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO–TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune‐related adverse events (irAEs) from TKI‐related adverse events (TKI‐AEs) is challenging because of overlapping clinical features. We aimed to evaluate whether eosinophil counts can help differentiate between them.